期刊文献+

多发性骨髓瘤患者MMP-2及VEGF表达的研究 被引量:2

Studies of MMP-2 and VEGF expression in multiple myeloma patients
全文增补中
导出
摘要 目的探讨基质金属蛋白酶-2(MMP-2)、血管内皮细胞生长因子(VEGF)水平与多发性骨髓瘤(MM)的病情进展的关系和临床意义。方法用酶联免疫吸附试验(ELISA)分别检测了24例MM患者和10例正常对照骨髓基质细胞(BMSC)培养上清液的MMP-2、VEGF水平。结果14例进展期MM组的MMP-2、VEGF表达水平显著高于10例稳定期MM组和10例正常对照组(P【0.05),稳定期MM组和正常对照组的MMP-2水平差异无统计学意义(P】0.05),稳定期MM组VEGF水平高于正常对照组(P【0.05)。9例进展期MM组的BMSC与人骨髓瘤细胞系细胞U266(终浓度2×10~5/ml)进行混合培养48 h后,其上清中MMP-2、VEGF水平明显增高,显著高于进展期MM、稳定期MM、正常对照组BMSC及稳定期MM BMSC+U266组的水平(均为P【0.05)。稳定期MM BMSC+U266组的VEGF水平显著高于进展期MM、稳定期MM、正常对照组BMSC(P【0.05),差异有统计学意义。MMP-2与VEGF两者呈正相关(r=0.925,P【0.05)。结论MMP-2、VEGF水平升高与MM的病情进展或发病有关,该过程可能需骨髓瘤细胞和骨髓基质细胞协同作用而完成。 Objective To explore the role and implication of matrix metalloproteinase-2(MMP-2) and vascular endothelial growth factor (VEGF)in multiple myeloma (MM).Methods Expression MMP-2 and VEGF secreted by bone marrow stromal cells (BMSC) of 24 MM patients were detected by ELISA.Results The level of MMP-2 and VEGF in 14 active MM patients were significantly higher than 10 stable MM pa- tients and 10 healthy subjects(P<0.05),The level of VEGF in stable MM patients were different from healthy subjects(P<0.05) When human MM cell lines U266 were adhered to BMSC of 9 active MM patients.The level of MMP-2 and VEGF in active and stable MM patients were significantly higher than BMSC alone (P<0.05). The expression level of MMP-2 was related to VEGF (r=0.925,P<0.05).Conclusion The increase of MMP-2 and VEGF activity produced by BMSC or induced by myeloma cells in these cocultures is associated with progress or pathogenesis of MM,and may be invoved with tumor invasion.
出处 《白血病.淋巴瘤》 CAS 2007年第3期174-175,179,共3页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 基质金属蛋白酶-2 血管内皮细胞生长因子 Multiple myeloma Matrix metalloproteinase-2 Vascular endothelial growth factor
  • 相关文献

参考文献1

二级参考文献8

  • 1Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.Semin Oneol, 2001, 28: 551-559.
  • 2Dankbar B, Padre T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell in teractions inmultiple myeloma. Blood, 2000, 95 : 2630-2636.
  • 3Anderson KC. Multiple myeloma. Advances in disease biology:therapeutic implication. Semin Hematol, 2001,38 (2 Suppl 3) : 6-10.
  • 4Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal ceils upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 2001,15 : 1950-1961.
  • 5Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.Blood, 2003, 101: 2775-2783.
  • 6Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myloma cell growth in the bone marrow milieu.Blood, 2003, 101 : 703-705.
  • 7Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor a in the pathophysiology of human multiple myeloma:therapeutic applications. Oncogene, 2001,20: 4519-4527.
  • 8Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibior PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res, 2002, 62 : 5019-5026.

共引文献10

同被引文献27

  • 1Yuregir 00,Yurtcu E,Kizilkilic E,et al.Detecting methylation patterns of pl6,MGMT,DAPK and E-cadherin genes in multiple myeloma patients.Int J Lab Hematol,2009,[Epub ahead of print].
  • 2Kenneth JL,Thomas D.Analysis of relative gene expression date using real-time quantitative PCR and the 2-△△Ct method.Methods,2001,25:402-408.
  • 3Kouzarides T.Chromatin modifications and their function.Cell,2007,128:693-705.
  • 4Bannister AJ,Kouzarides T.Reversing histone methylation.Nature,2005,436:1103-1106.
  • 5Marmorstein R,Trevel RC.Histone modifying enzymes:structures,mechanisms,and specificities.Biochim Biophys Acta,2009,1789:58-68.
  • 6Yoshizak T,Sato H,Frukawa M.Recent advances in the regulation of matrix metallo-proteinase 2 activation:from basic research to clinical implication.Oncol Rep,2002,9:607-611.
  • 7Clouaire T,Stancheva I.Methyl-CpG binding proteins:specialized transcriptional repressors or structural components of chromatin.Cell Mol Life Sci,2008,65:1509-1522.
  • 8Leone G,Voso MT,Teofili L,et al.Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.Clin Immunol,2003,109:89-102.
  • 9Kini AR, Peterson LA, Tallman MS, et al. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-transretinoic acid. Blood, 2001, 97:3919-3924.
  • 10Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 2000, 95: 309-313.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部